Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by ValuEngine

Denali Therapeutics (NASDAQ:DNLI) was downgraded by equities researchers at ValuEngine from a “strong-buy” rating to a “buy” rating in a report released on Thursday, ValuEngine reports.

Several other research firms have also weighed in on DNLI. TheStreet lowered Denali Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, June 13th. Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Tuesday, July 23rd. Finally, HC Wainwright set a $28.00 target price on Denali Therapeutics and gave the stock a “buy” rating in a report on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $25.50.

Shares of Denali Therapeutics stock traded down $1.27 during trading on Thursday, hitting $19.02. 318,420 shares of the stock traded hands, compared to its average volume of 250,657. The company has a market capitalization of $2.04 billion, a PE ratio of -48.77 and a beta of 2.12. The company has a current ratio of 11.55, a quick ratio of 11.55 and a debt-to-equity ratio of 0.14. Denali Therapeutics has a twelve month low of $13.68 and a twelve month high of $28.86. The business’s fifty day moving average is $20.48.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.01). The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $12.88 million. Denali Therapeutics had a negative net margin of 38.84% and a negative return on equity of 10.23%. As a group, analysts forecast that Denali Therapeutics will post -1.54 earnings per share for the current fiscal year.

In related news, COO Alexander O. Schuth sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $20.28, for a total value of $152,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ryan J. Watts sold 18,333 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $19.07, for a total value of $349,610.31. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 111,666 shares of company stock valued at $2,272,053. Corporate insiders own 21.20% of the company’s stock.

Several hedge funds have recently modified their holdings of DNLI. Wasatch Advisors Inc. lifted its holdings in shares of Denali Therapeutics by 1,702.4% during the first quarter. Wasatch Advisors Inc. now owns 820,904 shares of the company’s stock worth $19,061,000 after buying an additional 775,358 shares during the last quarter. Chicago Equity Partners LLC acquired a new position in shares of Denali Therapeutics during the second quarter worth approximately $2,438,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Denali Therapeutics during the second quarter worth approximately $1,520,000. Baillie Gifford & Co. lifted its holdings in shares of Denali Therapeutics by 0.6% during the first quarter. Baillie Gifford & Co. now owns 6,262,226 shares of the company’s stock worth $145,408,000 after buying an additional 34,502 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Denali Therapeutics during the second quarter worth approximately $680,000. Institutional investors own 71.70% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Featured Article: Different Types of Derivatives

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.